In this regard, it was demonstrated that the TA-CDK inhibitors THZ1, which simultaneously inhibits CDK7, CDK12 and CDK13, and THZ531, which selectively targets CDK12/13, strongly impaired viability of medulloblastoma (MB) cells, with a significant selectivity toward MYC-amplified cell lines [39, 94]. This evidence concerns the gene CDK12 and medulloblastoma.